natgillin/translations-raw huggingface dataset:
the therapeutic effect is a measured parameter selected from IGF-1 concentrations, IGFBP3 concentration, height velocity, lean body mass, total body fat, trunk fat, response to insulin challenge, rate of division of chondrocytes, chondrocyte numbers, bone density, bone growth, and increase in epiphyseal plate width. A method of producing a fusion protein comprising growth hormone fused to one or more extended recombinant polypeptides (XTEN), comprising: 
je terapeutski učinak mjerni parametar koji se odabire od koncentracije IGF-1, koncentracije IGFBP3, brzine rasta, oslabljene tjelesne mase, ukupne tjelesne masnoće, masnoće trupa, reakcije na izlaganje inzulinu, brzine podjele hondrocita, broja hondrocita, gustoće kostiju, rasta kostiju, te povećanja širine epifizne ploče.
An antibody or antigen-binding fragment thereof, which specifically binds human interleukin-6 receptor (hIL-6R) with a KD of 500 pM or less, as measured by surface plasmon resonance, wherein: 
Antitijelo ili njegov fragment koji se veže na antigen, koji se specifično veže na receptor humanoginterleukina 6 (hIL-6R) sa konstantom Kp od 500 pM ili manje, izmjereno površinskom plazmon rezonancijom, naznačen time, da:
The method of claim 5, wherein the bacterial infection is caused by Enterobacteriaceae. The method of claim 5, wherein the bacterial infection is caused by an Acinetobacter spp. pathogen, Pseudomonas aeruginosa, or Burkholderia spp. pathogen. 
Kombinacija za upotrabu sukladno bilo kojem od patentnih zahtjeva 4 do 6, naznačena time da je bakterijska infekcija prouzročena Enterobacteriaceae patogenom, Acinetobacter spp. patogenom, P. aeruginosa patogenom, ili Burkholderia spp. patogenom.
q is an integer ranging from 0 to 6; 
q je cijeli broj u opsegu od 0 do 6;
a milk powder, such as e.g. skimmed milk powder, and wherein optionally, the solids of the denatured whey protein composition are in an amount of at least 25% (w/w), optionally, the food ingredient powder has a total protein: ash content weight ratio of at least 15, optionally, the food ingredient powder has a lactose content of at most 35% (w/w), and optionally, the food ingredient powder has a low fat content of at most 8% (w/w). 
mlijeko u prahu, poput primjerice obranog mlijeka u prahu, i gdje čvrste tvari pripravka denaturiranog proteina sirutke mogu biti u količini od najmanje 25 % (tež./tež.), sastojak hrane u prahu može imati težinski omjer ukupni protein:sadržaj pepela od najmanje 15, sastojak hrane u prahu može imati sadržaj laktoze od najviše 35 % (tež./tež.), te sastojak hrane u prahu može imati nizak sadržaj masti od najviše 8 % (tež./tež.).
Via an opening 8, connected to pressure control means, in this case the pump system 11, the pressure within the channel part 7 can be adjusted to a value d2, which is lower than the pressure d1 in the space of the reinforcement package 2. 
Preko otvora 8 spojeno je sredstvo za kontrolu pritiska, u ovom slučaju sistem pumpe 11, i pritisak unutar dijela kanala 7 može se namjesti na vrijednost d2, koji je niži od pritiska d1 u prostoru tijela za ojačanje 2.
R2′ is hydrogen; (C1-C4)alkyl optionally substituted with a methoxy; or a phenyl group, the phenyl group being optionally substituted with a methoxy group; is hydrogen; or (C1-C4)alkyl; 
R* je vodik; (C,-C,)alkil koji može biti supstituiran s metoksi; ili fenilna skupina koja može biti supstituirana s metoksi skupinom; R? je vodik; ili (C;-Cy)alkil;
The method according to any one of the preceding claims, wherein the number of oil droplets having a size of >1.2 µm in the second emulsion is 5 x 1010 /ml or less. 
Postupak prema bilo kojem zahtjevu od 1-3, naznačen time da broj uljnih kapljica koje imaju veličinu od >1.2 um u drugoj emulziji je 5 x 10/* /ml ili manje.
n is selected from the group consisting of 0 and 1; and 
Spoj ili sol prema zahtjevu 1, naznačen time, da je m odabran iz skupine koju čine 0 i 1;
The method according to claim 1, wherein the glycosylated polypeptide is selected from the group comprising a polypeptide having a primary amino acid sequence of a human glycosylated polypeptide, a primary amino acid sequence of a non-human glycosylated polypeptide, a primary amino acid sequence of an antibody or an active fragment thereof, and/or a primary amino acid sequence of a non-mammalian glycosylated polypeptide. 
Metoda u skladu sa patentnim zahtjevom 1, gdje glikozilirani polipeptid je odabran iz grupe koja sadrži polipeptid koji ima primarnu aminokiselinsku sekvencu humanog glikoziliranog polipeptida, primarnu aminokiselinsku sekvencu ne-humanog glikoziliranog polipeptida, primarnu aminokiselinsku sekvencu antitijela ili njegovog aktivnog dijela, i/ili primarnu aminokiselinsku sekvencu glikoziliranog polipeptida koji nije porijeklom iz sisavaca.
is selected from the group consisting of hydrogen and lower alkyl; a is an integer from 1 to 2; is selected from the group consisting of and wherein b is an integer from 0 to 4; and wherein c is an integer from 0 to 2; each R5 is independently selected from the group consisting of halogen, lower alkyl and nitro; 
"o kO pri čemu b je cijeli broj od 0 do 4; i pri čemu c je cijeli broj od O do 2; svaki R> je nezavisno odabran iz skupine koja sadrži halogen, niži alkil i nitro; pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika, pod uvjetom da kada (R*hy CI
reacting an intermediate of formula (V) wherein R3 - R5 are as defined in claim 1, with an intermediate of formula (VII) wherein R, R1 and R2 are as is as defined in claim 1, in the presence of a base in a reaction inert solvent. 
reakciju s intermedijerom formule (V) [image] pri čemu su R3 - R5 kako je definirano u zahtjevu 1, s intermedijerom formule (VII) [image] pri čemu su R, R1 i R2 kako je definirano u zahtjevu 1, u prisutnosti baze u inertnom reakcijskom otapalu.
The pharmaceutical as claimed in claim 17, which comprises as a further active ingredient Verapamil, Gallopamii, Fendilin, Diltiazem, Nitrendipin, Felodipin, Amlodipin, Nifedipin, Lercanidipin, Nimodipin, Nicardipin, Lacidipin, Isradipin, Nisoldipin, Nilvadipin or Manidipin. 
Farmaceutski pripravak prema zahtjevu 17, naznačen time da kao dodatni aktivni sastojak sadrži Verapamil, Galopamil, Fendilin, Diltiazem, Nitrendipin, Felodipin, Amlodipin, Nifedipin, Lerkanidipin, Nimodipin, Nikardipin, Lakidipin, Isradipin, Nisoldipin, Nilvadipin ili Manidipin.
A pharmaceutical composition comprising a compound of any one of claims 1 - 16 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 
Farmaceutska smjesa, naznačena time, što sadrži monodisperznu smjesu iz bilo kojeg od zahtjeva 1-7 i farmaceutski prihvatljivi ekscipijent.
This is also referred to as macrogol 15-hydroxystearate or polyethylene glycol 15-hydroxystearate. 
Ona se također naziva i Macrogol 15-hidroksistearat ili polietilen glikol 15-hidroksistearat.
The genetically modified mouse of claim 12, wherein the humanized IL-6 gene is under control of endogenous mouse regulatory elements. 
Genetički modificirani miš prema zahtjevu 12, naznačen time da je humanizirani IL-6 gen pod kontrolom regulacijskih elemenata endogenog miša.
The method of claim 1, wherein the risperidone/copolymer mass ratio is about 33%, expressed as the weight percentage of the risperidone with respect to the risperidone plus copolymer. 
Sastav u skladu s bilo kojim od prethodnih zahtjeva pri čemu je omjer mase otapala/lijeka niži od 11,4% težinskog faktora/težinskog faktora izražen kao postotak težine otapala s obzirom na lijek.
The use of claim 19, wherein the second therapeutic agent is quinidine sulfate. The use of claim 19 or 20, wherein the dosage amount of the compound of Formula I or pharmaceutically acceptable salt thereof is 10-60 mg, and the dosage amount of quinidine is 2.5-30 mg. 
Uporaba u skladu s patentnim zahtjevom 22 ili 23, pri čemu je drugi terapiski agens kinidin, 1 pri čemu je količina doziranja tvari formule I ili njene farmaceutski prihvatljive soli 10-60 mg, a količina doziranja kinidina je 2.5-30 mg.
is chosen from the group consisting of the following groups: 
R: je izabran iz sljedećih skupina:
Method as claimed in the preceding claims characterized by wholly coating the bottom of the said formwork with a layer of non woven fabric or equivalent sealing means. 
Postupak za izradu ploče prema prethodnim zahtjevima, naznačen time što se vrši kompletnim oblaganjem donje strane spomenutog okvira slojem netkanog tekstilnog materijala ili ekvivalentne barijere.
precipitation of impurities by lowering the pH below pH 5 and by removal of the precipitate by filtration; 
taloženja nečistoća snižavanjem pH ispod pH 5 i uklanjanjem taloga filtriranjem;
A compound of claim 5, of formula (I-L): wherein 
Spoj sukladno patentnom zahtjevu 5, formule (I-L): ž a
Xanthane gum used in the compositions according to the invention is a natural polysaccharide produced by the microorganism Xantomonas campestris. 
Ksantanska guma koja se rabi u smjesama sukladno ovom izumu je prirodni polisaharid kojega proizvode mikroorganizmi Kantomonas campestris.
The method according to claim 13, wherein said effective inflammatory mediator release-reducing amount of said peptide comprises a degranulation-inhibiting amount of peptide that reduces the amount of an inflammatory mediator released from at least one inflammatory cell from about 1% to about 99% or preferably about 5-50% to about 99%, as compared to the amount released from at least one inflammatory cell in the absence of the peptide. 
Peptid za primjenu prema bilo kojem od prethodnih zahtjeva, naznačen time da stvarna količina spomenutog peptida koji smanjuje otpuštanje posrednika upale sadrži jednu količinu koja inhibira degranulaciju tog peptida koji smanjuje otpuštanje najmanje jednog posrednika upale koji se otpušta iz najmanje jedne upalne stanice za 5 do 99% u usporedbi s količinom koja bi bila otpuštena iz najmanje jedne upalne stanice da nema tog peptida.
The process for making a caspofungin composition according to claim 7, wherein step a) is performed by firstly preparing an aqueous solution comprising a pharmaceutically effective amount of a succinate buffering agent; and then adding to said solution of buffering agent a pharmaceutically acceptable amount of one or more excipients dissolved in water. 
Postupak pripreme smjese kaspofungina prema zahtjevu 8, naznačeno time da se korak a) provodi prvo pripremom vodene otopine koja obuhvaća farmaceutski djelotvornu količinu puferskog sredstva, pri čemu je pufersko sredstvo sukcinat; a zatim dodavanjem farmaceutski prihvatljive količine jedne ili više pomoćnih tvari otopljenih u vodi navedenoj otopini puferskog sredstva.
A composition for use according to claim 1 or claim 2, wherein the member selected from the group consisting of an acetylaminopropane sulfonate and an acetylaminopropane sulfonate salt decreases neuronalglutamatergic signaling. 
Pripravak za primjenu prema zahtjevu 1 ili zahtjevu 2, naznačen time da spomenuti element izabran iz skupine koju čine acetil aminopropan sulfonat i neka sol acetil aminopropan sulfonata smanjuje glutamatergičnu neurotransmisiju signala.
The present invention relates to a process for the preparation of estra-1,3,5(10)-trien-3,15a,16a,17B-tetraol I which comprises the steps of: 
HR P20161467 T1 PATENTNI ZAHTJEVI Postupak za pripremu estra-1,3,5(10)-trien-3,154, 160, 17B-tetraol I koji obuhvaća sljedeće korake:
converting said compound of formula (V) into a nitrile compound of formula (VI): 
(ili) pretvorba spoja formule (V) u odgovarajući nitrilni derivat spoja formule (VI),
Method according to any one of embodiments 1-3, wherein the anti-photogreying additive is present in the photocatalytic dispersion (10) in a concentration higher than 0.1 wt.%, preferably higher than 1 wt.%, more preferably higher than 5 wt.%. 
Postupak prema zahtjevima od 1-3, naznačen time da je dodatak protiv promjene boje pod utjecajem svijetlosti prisutan u fotokatalitičkoj disperziji (10) u koncentraciji većoj od 0,1% težine, poželjno višoj od 1% težine, poželjnije višoj od 5% težine.
The process according to any one of the preceding claims, wherein the hydrophobised ground calcium carbonate and/or the hydrophobised precipitated calcium carbonate obtained in step d) is used in powder form and/or in the form of granules or in the form of slurry. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da se hidrofobirani prirodni kalcijev karbonat i/ili hidrofobirani taložni kalcijev karbonat koji je dobiven u koraku d) koristi u praškastom obliku i/ili u obliku granula ili u obliku suspenzije. HR P20160787 T1
The composition of claim 6, wherein the composition is free of tannic acid. 
Sastav prema patentnom zahtjevu 6, naznačen time, da u sastavu nema taninske kiseline.
This led to an increase in the fraction of non-fucosylated oligosaccharides attached to the Fc region of the antibodies, including bisected non-fucosylated oligosaccharides, as has been described in WO 2004/065540 (Figures 17-19). 
Protutijelo prema zahtjevu 13, naznačeno time, da spomenuto protutijelo ima povećanje u frakciji prepolovljenih vrsta ne-fukoziliranih oligosaharida priključenih na navedeno Fc-područje koje je pod glikoinženjeringom.
represents a pyperidyl group represented by the general formula (A1): (wherein R3 represents: 
R* predstavlja piperidinilnu skupinu prikazanu općom formulom (A1): -R*
The method according to claim 2, wherein the waste material supplied in the third portion is fly ash. 
Postupak sukladno zahtjevu 2, pri čemu je otpadni materijal koji se doprema u treći dio pepeo.
One embodiment of the present invention pertains to compounds of Formula (I) wherein R1 is selected from the group consisting of H, halogen, hydroxy, C1-4 haloalkyl, C1-4 alkyl, C1-4 alkoxy, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkylthio, and C1-4 haloalkoxy. 
Jedan oblik prikazanog izuma se odnosi na spojeve Formule (I) gdje R, je izabran iz skupine koju čine H, halogen, hidroksi, Ci.4 haloalkil, C,.4 alkil, C,4 alkoksi, C>.4 alkenil, C2.4 alkinil, C,.4 alkiltio, te C,.4 haloalkoksi.
A pharmaceutical composition comprising a compound of claims 1 and a pharmaceutically acceptable carrier, adjuvant or vehicle. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema zahtjevu 1 1 farmaceutski prihvatljiv nosač, pomoćno sredstvo 1li prijenosno sredstvo.
preparing a compound of formula 46 via pyrrolation of a compound of formula 47; 
pripravu spoja s formulom 46 putem pirolacije spoja s formulom 47;
A container according to claim 1, wherein the thickness of the seal layer is from 15 µm to 50 µm, preferably 20 µm. 
Posuda prema bilo kojem od prethodnih Zahtjeva, gdje je debljina sloja za spajanje fitma poklopca od 15 um do 50 um, a poželjno 20 um.
The method of any one of claims 1 to 13, wherein said target molecule is selected from the group consisting of a protein, a peptide, a carbohydrate, a polysaccharide, a glycoprotein, a hormone, a receptor, an antigen, an antibody, a virus, a substrate, a metabolite, a transition state analog, a cofactor, an inhibitor, a drug, a dye, a nutrient, a growth factor, a tissue, and a controlled substance, preferably wherein said target molecule is a protein or a peptide. 
14. Postupak prema bilo kojem od zahtjeva 1 do 13, naznačen time, da je navedena ciljana molekula odabrana iz skupine koju čine: protein, peptid, ugljikohidrat, polisaharid, glikoprotein, hormon, receptor, antigen, protutijelo, virus, supstrat, metabolit, analog prijelaznog stanja, kofaktor, inhibitor, lijek, boja, nutrijent, faktor rasta, tkivo i kontrolirana supstanca, pri čemu je navedena ciljana molekula poželjno protein ili peptid.
A method according to claim 1 or 2, wherein the collection of binding molecules on the surface of replicable genetic packages is a single chain Fv library. 
Postupak prema zahtjevu 1 ili 2, naznačen time da je kolekcija molekula za vezanje na površini replikativnih genetskih paketa Fv zbirka jednostrukog lanca.
There is also described methods for use in producing taxane analogs and derivates thereof for use in cancer treatment. 
Također su opisani postupci koji se koriste u proizvodnji analoga taksana 1 njihovih derivata za upotrebu u liječenju karcinoma.
The remaining solids were re-suspended in ethyl acetate and NaHCO3 (sat.) 
Preostale krutine se resuspendiraju u etil acetatu i NaHCO: (zas.)
The submerged combustion melter of claim 1 in which the open end of the middle tube protrudes beyond the open end of the internal tube connected to a source of oxygen-containing gas. 
Peć za taljenje s uronjenim izgaranjem u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačena time što otvoreni kraj srednje cijevi (9) viri dalje od otvorenog kraja unutarnje cijevi (3), spojenog na izvor plina koji sadrži kisik (7).
In another aspect, the invention provides a compound of the formula (1) 
PATENTNI ZAHTJEVI Kombinacija koja sadrži kiselinsku adicijsku sol spoja formule (1) o
The use of a compound as claimed in any one of claims 1 to 6 in the preparation of an agent for the treatment of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis and also other PGD2-mediated diseases, for example autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematus, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury, chronic obstructive pulmonary disease, as well as rheumatoid arthritis, psoriatic arthritis and osteoarthritis and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, stroke and amyoptrophic lateral sclerosis. 
Primjena spoja prema bilo kojem od patentnih zahtjeva 1 do 6, naznačena time što se koristi u pripremi sredstva za liječenje alergijske astme, perenijalnog alergijskog rinitisa, sezonskog alergijskog rinitisa, atopijskog dermatitisa, kontaktne hipersenzitivnosti (uključujući kontaktni dermatitis), konjunktivitisa, posebnoo alergijskog konjunktivitisa, eozinofilnog bronhitisa, alergija na hranu, eozinofilnog gastroenteritisa, inflamatorne bolesti crijeva, ulceroznog kolitisa i Crohn-ove bolesti, mastocitoze i također drugih PGD;-posredovanih bolesti, na primjer autoimunih bolesti kao što je hiper IgE sindrom i sistemski lupus eritematodes, psolrijaza, akne, multipla skleroza, odbacivanje alotransplanta, reperfuziona povreda, kronična opstruktivna bolest pluća, kao i reumatoidni artritis, psolrijatički artritis i osteoartritis i neurodegenerativne bolesti kao što su Alzheimer-ova bolest, Parkinsolnova bolest, šlog i amiotrofna lateralna skleroza.
It is also to be understood that certain compounds of the Formula I may exist in solvated as well as unsolvated forms such as, for example, hydrated forms. 
Također se podrazumijeva da određeni spojevi prikazani Formulom I mogu postojati u solvatiranim, kao i u nesolvatiranim oblicima poput, na primjer, hidratiranih oblika.
The compound for use according to claim 12, wherein the RNA viral polymerase is a polymerase selected from the group consisting of Ebola, West Nile, yellow fever, Dengue fever, influenza A, influenza B, Rift Valley Fever, and Marburg viral polymerases. 
Spoj za primjenu prema zahtjevu 5 ili 6, naznačen time da je druga virusna RNK polimeraza izabrana iz grupe koja se sastoji od virusnih polimeraza adenovirusa, influenca A virusa, influenca B virusa, parainfluenca virusa, respiratornog sincicijalnog virusa, rinovirusa, Junin virusa, Pichinde virusa, virusa groznice doline Rift, virusa denga groznice, virusa morbila, virusa žute groznice, Takaribe virusa, virusa venecuelanskog konjskog encefalitisa, virusa Zapadnog Nila, i SARS-CoV virusa.
from 45% to 50% by weight on a dry weight basis of a pharmaceutically acceptable microcrystalline cellulose; 
od 45 do 50 masenih postotaka na bazi suhe mase farmaceutski prihvatljive mikrokristalne celuloze;
Process according to claim 5, further comprising the preparation of 6-methyl-2-benzo[b]thiophenecarboxylic acid (1) by means of catalytic hydrodehalogenation on Pd/C of 3-chloro-6-methyl-2-benzo[b]-thiophenecarboxylic acid (18) 
Postupak prema patentnom zahtjevu 5, naznačen time da dalje obuhvaća pripravu 6-metil-2-benzo[b] tiofenkarboksilne kiseline (1) katalitičkim hidrogeniranjem 3-klor-6-metil-2-benzo[b]tiofenkarboksilne kiseline (18) uz Pd/C.
The process of claim 8, wherein the supercritical hydrothermolysis is carried out in a fixed-bed, fluidized-bed, or entrained-bed reactor (18), with or without inert materials, at a residence time in the range from 3 to 60 minutes at supercritical water conditions. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time, da se nadkritična hidrotermoliza vrši u reaktoru sa fiksnim slojem, fluidnim slojem ili reaktorom s unutarnjim slojem (18), sa ili bez inertnih materijala, u vremenu zadržavanja u rasponu od 3 do 60 minuta pri nadkritičnim vodenim uvjetima.
the electrodes (104,106) are configured to align and connect to an electric outlet; the material (114) infused with the fragrance is a solid in the shape of a flat ring; and the cap (116) includes a vent (110) effective to disperse the fragrance. 
Postupak prema zahtjevu 4, naznačen time, da: su elektrode (104, 106) konstruirane na takav način, da su poravnate i spojene s električnom utičnicom; se kod materijala (114) koji je natopljen s aromom, radi o krutoj tvari u obliku plosnatog prstena; i kapica (116) obuhvaća ventil (110) koji je djelotvoran za raspršivanje arome.
The orally dispersing tablet of claim 1, which is free of lubricant. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 1, koja ne sadrži lubrikant.
To improve the assembly of the container and also the corresponding method of fabricating it may be advantageous if the corresponding spots or areas are evenly distributed. 
Da bi sc poboljšala montaža spremnika, a također i odgovarajući postupak proizvodnje, može biti povoljno da su odgovarajuće točke ili odgovarajuća područja raspoređeni ravnomjerno.
a fluid injection member for injecting a fluid under pressure into the capsule, the pressure of the fluid injection assisting in the opening of the outlet face, wherein: 
- < element za injektiranje fluida koji injektira fluid pod tlakom u čahuru (1), pri čemu tlak injektiranog fluida pomaže pri otvaranja izlazne plohe, i pri čemu:
reducing the azide group of the compound of Formula-IV to form an amine group and isolating the compound of Formula-Ia; and 
redukciju azidne grupe u spoju formule-IV da bi se dobila amino grupa i izolirao spoj formule-Ia; i [image]
optionally adjusting the pH value of this aqueous solution or suspension to pH<7, 
(b) opcionalno prilagođavanje pH vrijednosti vodene otopine ili suspenzije vrijednosti pH <7,
A pharmaceutical composition according to any one of paras. 1 to 13, wherein said arginine, if present, is: free arginine or a pharmaceutically acceptable salt of arginine. 
Farmaceutski sastav prema zahtjevu 1 ili 2, naznačen time, da spomenuti arginin je slobodni arginin ili farmaceutski prihvatljiva sol od arginina.
A modified soluble FGF receptor Fc fusion of claim 26 wherein said chemotherapeutic agent is selected from the group: anti-microtubule agents; platinum coordination complexes; alkylating agents; antibiotic agents; topoisomerase II inhibitors; antimetabolites; topoisomerase I inhibitors; hormones and hormone analogues; signal transduction pathway inhibitors; non-receptor tyrosine kinase angiogenesis inhibitors; immunotherapeutic agents; pro-apoptotic agents; and cell cycle signaling inhibitors. 
Modificirana fuzija između topivog FGF receptora i Fc u skladu s patentnim zahtjevom 33, naznačena time što navedeno kemoterapijsko sredstvo se bira iz skupine koju čine antimikrotubularna sredstva, platinski koordinacijski kompleksi, alkilacijska sredstva, antibiotička sredstva, inhibitori topoizomeraze Il; antimetaboliti, inhibitori topoizomeraze I, hormoni i hormonski analozi, inhibitori puteva prijenosa signala, inhibitori nereceptorske angiogene tirozin-kinaze, imunoterapijska sredstva, proapoptotska sredstva, te inhibitori signalizacije staničnog ciklusa.